Medical Products was the largest of Baxter International Inc’s 2 reported lines in fiscal 2011, at $7.84B — 56% of $13.89B.
| Segment Information By Entity | FY 2010 | FY 2011 |
|---|---|---|
| Medical Products | $7.20B | $7.84B |
| Bioscience | $5.64B | $6.05B |
| Total | $12.84B | $13.89B |
In fiscal 2011, which ended December 31, 2011, the 2 segments Baxter International Inc reported in this breakdown added up to $13.89B. That was up 8.2% from $12.84B in fiscal 2010. Medical Products was the largest segment, at $7.84B or 56.4% of the total, followed by Bioscience ($6.05B, 43.6%).
Compared with fiscal 2010, Medical Products grew the fastest, rising 8.8% to $7.84B.
This breakdown covers every fiscal year from 2010 to 2011, as reported in Baxter International Inc's annual filings.
U.S. & Puerto Rico Plans was the largest of Baxter International Inc’s 4 reported lines in fiscal 2018, at $4.72B — 43% of $11.10B.
| Geography | FY 2008 | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| U.S. & Puerto Rico Plans | — | — | $4.51B | $4.72B | |||||||
| Americas | $4.00B | $4.26B | $4.51B | — | |||||||
| Us | — | — | — | — | |||||||
| U S | — | — | — | — | |||||||
| Consolidated Net Sales | — | — | — | — | |||||||
| United States | — | — | — | — | |||||||
| Europe | $2.77B | $2.70B | $2.73B | — | |||||||
| Emea | — | $2.70B | $2.75B | $2.95B | |||||||
| Apac | $1.97B | $2.03B | $2.11B | $2.20B | |||||||
| Asia Pacific | — | — | — | — | |||||||
| Asia-Pacific | — | — | — | — | |||||||
| Latin America & Canada | $1.22B | $1.18B | $1.21B | $1.23B | |||||||
| Total | $9.97B | $12.86B | $17.82B | $11.10B |
In fiscal 2018, which ended December 31, 2018, the 4 regions Baxter International Inc reported in this breakdown added up to $11.10B. The regions reported changed from fiscal 2017, so the total is not directly comparable with the $17.82B reported that year. U.S. & Puerto Rico Plans was the largest region, at $4.72B or 42.6% of the total, followed by Emea ($2.95B, 26.5%) and Apac ($2.20B, 19.8%). Together, the two largest regions made up 69.1% of this total.
Compared with fiscal 2017, Emea grew the fastest, rising 7.0% to $2.95B. Every sizeable region reported in both years grew. Because regions were added or dropped between the two years, part of this reflects how Baxter International Inc regrouped its reporting.
U.S. & Puerto Rico Plans (fiscal 2017) and Emea (fiscal 2016) were first reported as separate regions during this period. The table also keeps 8 regions that Baxter International Inc no longer reports, so earlier years can still be read on their original basis; use "Show 8 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2008 to 2018, as reported in Baxter International Inc's annual filings.
Americas was the largest of Baxter International Inc’s 3 reported lines in fiscal 2020, at $6.32B — 54% of $11.67B.
| Segment | FY 2009 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 |
|---|---|---|---|---|---|---|---|---|---|---|
| Medical Products | — | — | — | — | ||||||
| Americas | $5.72B | $5.95B | $6.31B | $6.32B | ||||||
| Bioscience | — | — | — | — | ||||||
| Bio Science | — | — | — | — | ||||||
| Renal | — | — | — | — | ||||||
| Emea | $2.75B | $2.95B | $2.76B | $2.88B | ||||||
| Hospital Products | — | — | — | — | ||||||
| Apac | $2.11B | $2.20B | $2.30B | $2.48B | ||||||
| Business Segment Other | — | — | — | — | ||||||
| Total | $10.58B | $11.10B | $11.36B | $11.67B |
In fiscal 2020, which ended December 31, 2020, the 3 segments Baxter International Inc reported in this breakdown added up to $11.67B. That was up 2.7% from $11.36B in fiscal 2019. Americas was the largest segment, at $6.32B or 54.2% of the total, followed by Emea ($2.88B, 24.6%) and Apac ($2.48B, 21.2%). Together, the two largest segments made up 78.8% of this total.
Compared with fiscal 2019, Apac grew the fastest, rising 7.6% to $2.48B. Every sizeable segment reported in both years grew. Over fiscal 2017 to 2020, revenue across these segments went from $10.58B to $11.67B, a compound annual growth rate of 3.3%. Americas held a steady share of about 54.2%.
The table also keeps 6 segments that Baxter International Inc no longer reports, so earlier years can still be read on their original basis; use "Show 6 discontinued" beneath the table to see them. This breakdown covers 10 fiscal years between 2009 and 2020, as reported in Baxter International Inc's annual filings.
Baxter International Inc (BAX) breaks its revenue down by segment and region. In fiscal 2011, its largest segment was Medical Products, with $7.84B or 56.4% of the total, followed by Bioscience at $6.05B (43.6%).
Medical Products was Baxter International Inc's largest segment in fiscal 2011, with $7.84B in revenue, 56.4% of the $13.89B reported across its 2 segments.
U.S. & Puerto Rico Plans was Baxter International Inc's largest region in fiscal 2018, with $4.72B in revenue, 42.6% of the $11.10B reported across its 4 regions.
Of the Baxter International Inc segments reported in both fiscal 2010 and fiscal 2011, and making up at least 2% of the total, Medical Products grew the fastest, rising 8.8% from $7.20B to $7.84B.
Every figure is taken from Baxter International Inc's annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by segment covers fiscal 2010 to 2011. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.